WO2006021692A8 - Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif - Google Patents

Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif

Info

Publication number
WO2006021692A8
WO2006021692A8 PCT/FR2005/002092 FR2005002092W WO2006021692A8 WO 2006021692 A8 WO2006021692 A8 WO 2006021692A8 FR 2005002092 W FR2005002092 W FR 2005002092W WO 2006021692 A8 WO2006021692 A8 WO 2006021692A8
Authority
WO
WIPO (PCT)
Prior art keywords
gastric
pharmaceutical composition
active principle
tablet containing
resident
Prior art date
Application number
PCT/FR2005/002092
Other languages
English (en)
Other versions
WO2006021692A1 (fr
Inventor
Gerard Alaux
Estelle Chouin
Nathalie Dufresne-Arokiassamy
Original Assignee
Sanofi Aventis
Gerard Alaux
Estelle Chouin
Nathalie Dufresne-Arokiassamy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006021692(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2005276307A priority Critical patent/AU2005276307B2/en
Priority to MX2007001957A priority patent/MX2007001957A/es
Priority to NZ553673A priority patent/NZ553673A/en
Priority to CA2577361A priority patent/CA2577361C/fr
Priority to JP2007526512A priority patent/JP5048492B2/ja
Priority to EP05798249A priority patent/EP1781295A1/fr
Priority to CN2005800311527A priority patent/CN101022808B/zh
Application filed by Sanofi Aventis, Gerard Alaux, Estelle Chouin, Nathalie Dufresne-Arokiassamy filed Critical Sanofi Aventis
Priority to EA200700217A priority patent/EA012981B1/ru
Priority to BRPI0514532-5A priority patent/BRPI0514532A/pt
Publication of WO2006021692A1 publication Critical patent/WO2006021692A1/fr
Priority to IL181150A priority patent/IL181150A0/en
Priority to US11/675,712 priority patent/US20070190140A1/en
Priority to ZA2007/01443A priority patent/ZA200701443B/en
Priority to NO20071315A priority patent/NO20071315L/no
Publication of WO2006021692A8 publication Critical patent/WO2006021692A8/fr
Priority to HK08101572.6A priority patent/HK1112575A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composition pharmaceutique sous forme d'un comprimé matriciel à résidence gastrique, comprenant un principe actif, caractérisée en ce qu' au contact avec un milieu représentatif du fluide gastrique , elle augmente après quinze minutes en volume, d'un taux de gonflement d'au moins 200%.
PCT/FR2005/002092 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif WO2006021692A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2007526512A JP5048492B2 (ja) 2004-08-19 2005-08-17 活性成分を含有する胃貯留錠の形態の薬学的組成物
BRPI0514532-5A BRPI0514532A (pt) 2004-08-19 2005-08-17 composição farmacêutica sob a forma de comprimido com permanência gástrica, contendo um princìpio ativo
EA200700217A EA012981B1 (ru) 2004-08-19 2005-08-17 Фармацевтическая композиция в форме таблетки для нахождения в желудке, содержащая активное вещество
CA2577361A CA2577361C (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
MX2007001957A MX2007001957A (es) 2004-08-19 2005-08-17 Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo.
EP05798249A EP1781295A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
CN2005800311527A CN101022808B (zh) 2004-08-19 2005-08-17 含有活性组分的胃滞留片剂的药物组合物
AU2005276307A AU2005276307B2 (en) 2004-08-19 2005-08-17 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
NZ553673A NZ553673A (en) 2004-08-19 2005-08-17 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
IL181150A IL181150A0 (en) 2004-08-19 2007-02-04 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
US11/675,712 US20070190140A1 (en) 2004-08-19 2007-02-16 Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle
ZA2007/01443A ZA200701443B (en) 2004-08-19 2007-02-19 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
NO20071315A NO20071315L (no) 2004-08-19 2007-03-09 Farmasoytisk preparat i form av en tablett inneholdende et aktivt prinsipp for opphold i magen.
HK08101572.6A HK1112575A1 (en) 2004-08-19 2008-02-13 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408986 2004-08-19
FR0408986A FR2874325B1 (fr) 2004-08-19 2004-08-19 Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/675,712 Continuation US20070190140A1 (en) 2004-08-19 2007-02-16 Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle

Publications (2)

Publication Number Publication Date
WO2006021692A1 WO2006021692A1 (fr) 2006-03-02
WO2006021692A8 true WO2006021692A8 (fr) 2007-04-12

Family

ID=34950702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002092 WO2006021692A1 (fr) 2004-08-19 2005-08-17 Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif

Country Status (23)

Country Link
US (1) US20070190140A1 (fr)
EP (1) EP1781295A1 (fr)
JP (1) JP5048492B2 (fr)
KR (1) KR20070046124A (fr)
CN (1) CN101022808B (fr)
AR (1) AR050696A1 (fr)
AU (1) AU2005276307B2 (fr)
BR (1) BRPI0514532A (fr)
CA (1) CA2577361C (fr)
EA (1) EA012981B1 (fr)
FR (1) FR2874325B1 (fr)
HK (1) HK1112575A1 (fr)
IL (1) IL181150A0 (fr)
MA (1) MA28862B1 (fr)
MX (1) MX2007001957A (fr)
MY (1) MY145832A (fr)
NO (1) NO20071315L (fr)
NZ (1) NZ553673A (fr)
PE (1) PE20060639A1 (fr)
TW (1) TWI357329B (fr)
UY (1) UY29073A1 (fr)
WO (1) WO2006021692A1 (fr)
ZA (1) ZA200701443B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205094B2 (en) 2006-12-22 2015-12-08 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008102235A1 (fr) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Formulations d'alfuzosine à libération contrôlée
JP2008280251A (ja) * 2007-05-08 2008-11-20 Shin Etsu Chem Co Ltd 多層錠及びその製造方法
CN102076215A (zh) 2008-06-30 2011-05-25 托卡根公司 5-氟胞嘧啶制剂及其用途
WO2011102506A1 (fr) * 2010-02-22 2011-08-25 第一三共株式会社 Préparation solide à libération prolongée pour usage oral
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10569071B2 (en) 2015-08-31 2020-02-25 Ethicon Llc Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US10245034B2 (en) * 2015-08-31 2019-04-02 Ethicon Llc Inducing tissue adhesions using surgical adjuncts and medicants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
DE4036757A1 (de) * 1990-11-17 1992-05-21 Bayer Ag Antazida-zubereitung mit verlaengerter magenverweilzeit
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
PT938318E (pt) * 1996-08-29 2001-10-30 Jagotec Ag Comprimido com libertacao controlada de cloridrato de alfuzosina
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6476006B2 (en) * 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2001268722B8 (en) * 2000-06-23 2005-09-29 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881424B1 (en) * 2000-09-05 2005-04-19 Mionix Corporation Highly acidic metalated organic acid
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
ATE477795T1 (de) * 2001-07-04 2010-09-15 Sun Pharma Advanced Res Co Ltd Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors

Also Published As

Publication number Publication date
KR20070046124A (ko) 2007-05-02
CN101022808B (zh) 2013-05-29
AR050696A1 (es) 2006-11-15
FR2874325A1 (fr) 2006-02-24
EA012981B1 (ru) 2010-02-26
US20070190140A1 (en) 2007-08-16
JP2008509973A (ja) 2008-04-03
FR2874325B1 (fr) 2006-10-20
TWI357329B (en) 2012-02-01
ZA200701443B (en) 2008-05-25
NZ553673A (en) 2010-10-29
EP1781295A1 (fr) 2007-05-09
CA2577361C (fr) 2013-10-01
AU2005276307A1 (en) 2006-03-02
WO2006021692A1 (fr) 2006-03-02
MY145832A (en) 2012-04-30
NO20071315L (no) 2007-03-09
CN101022808A (zh) 2007-08-22
IL181150A0 (en) 2007-07-04
EA200700217A1 (ru) 2007-08-31
CA2577361A1 (fr) 2006-03-02
BRPI0514532A (pt) 2008-06-17
JP5048492B2 (ja) 2012-10-17
TW200618802A (en) 2006-06-16
MX2007001957A (es) 2007-04-25
UY29073A1 (es) 2006-03-31
AU2005276307B2 (en) 2011-02-24
HK1112575A1 (en) 2008-09-12
PE20060639A1 (es) 2006-07-20
MA28862B1 (fr) 2007-09-03

Similar Documents

Publication Publication Date Title
WO2006021692A8 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
WO2007010034A3 (fr) Copolymere ampholyte, sa production et son utilisation
WO2005118008A3 (fr) Compositions et articles contenant une matrice polymere reticulee et un liquide actif immobilise et procedes de fabrication et d'utilisation de ceux-ci
IL245365A0 (en) ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses
WO2006091529A3 (fr) Preparation pharmaceutique solide
WO2007028937A3 (fr) Patch olfactif
WO2006078320A3 (fr) Procede de production de systemes d'administration, et systemes d'administration
WO2008128775A3 (fr) Composition pharmaceutique stabilisée contenant de la prégabaline
WO2005079384A3 (fr) Dispositif de retention gastrique expansible
WO2007022956A3 (fr) Compositions pharmaceutiques
WO2007072992A3 (fr) Preparation solide
WO2007012857A8 (fr) Formules topiques contenant de la sporopollénine
EG25188A (en) Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules.
EP1790336A4 (fr) Composition pour film de capsule, film de capsule et capsule constituée de celui-ci
WO2007036278A3 (fr) Procede pour stabiliser des formes galeniques pharmaceutiques contenant des micro-organismes
WO2006056696A3 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
WO2006023814A3 (fr) Composition effervescente comprenant un composant derive du raisin
WO2005123045A3 (fr) Formulation a dosage pharmaceutique contenant une matrice a liberation controlee
EP1561472A4 (fr) Preparation solide
WO2006046114A3 (fr) Formes posologiques osmotiques a taux croissant de liberation du medicament, et leurs procedes de preparation
WO2006109175A3 (fr) Forme posologique solide pour un medicament antidiabetique
WO2006007351A3 (fr) Forme posologique orale a liberation controlee par compression
WO2007141743A3 (fr) Forme pharmaceutique de comprimé comprenant de la cétirizine et de la pseudoéphédrine
WO2007016350A3 (fr) Preparation en comprimes a liberation modifiee presentant des proprietes mecaniques ameliorees
WO2006087629A3 (fr) Composition de medicament antipsychotique a delitement rapide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200700217

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2005798249

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 181150

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: DZP2007000096

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001957

Country of ref document: MX

Ref document number: 11675712

Country of ref document: US

Ref document number: 1020077003897

Country of ref document: KR

Ref document number: 12007500396

Country of ref document: PH

Ref document number: 2007526512

Country of ref document: JP

Ref document number: 2577361

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007/01443

Country of ref document: ZA

Ref document number: 07016432

Country of ref document: CO

Ref document number: 200701443

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 633/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 553673

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005276307

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580031152.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005276307

Country of ref document: AU

Date of ref document: 20050817

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005276307

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005798249

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11675712

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0514532

Country of ref document: BR